DK1969007T3 - Sammensætninger og fremgangsmåder til fremstilling af en sammensætning - Google Patents

Sammensætninger og fremgangsmåder til fremstilling af en sammensætning

Info

Publication number
DK1969007T3
DK1969007T3 DK06848052.4T DK06848052T DK1969007T3 DK 1969007 T3 DK1969007 T3 DK 1969007T3 DK 06848052 T DK06848052 T DK 06848052T DK 1969007 T3 DK1969007 T3 DK 1969007T3
Authority
DK
Denmark
Prior art keywords
compositions
preparing
composition
methods
Prior art date
Application number
DK06848052.4T
Other languages
English (en)
Inventor
Robert Donaldson
Ajoy Velayudhan
Kirk J Leister
Eugene J Schaefer
Ronald Bates
Elizabeth A Bramhall
David M Didio
Alan R Flesher
Helen G Haggerty
David H Kirkley
John M Tabor
Lee K Tay
Pallaiah Thammana
David E Smolin
Reb J Russell
Boom Thomas Vanden
Jeffrey Schrimsher
Joyce Whitehead
Dean Brownell
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38218674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1969007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1969007T3 publication Critical patent/DK1969007T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06848052.4T 2005-12-20 2006-12-19 Sammensætninger og fremgangsmåder til fremstilling af en sammensætning DK1969007T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75215005P 2005-12-20 2005-12-20
US75226705P 2005-12-20 2005-12-20
US84954306P 2006-10-05 2006-10-05
PCT/US2006/049074 WO2007076032A2 (en) 2005-12-20 2006-12-19 Compositions and methods for producing a composition

Publications (1)

Publication Number Publication Date
DK1969007T3 true DK1969007T3 (da) 2013-11-25

Family

ID=38218674

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06848052.4T DK1969007T3 (da) 2005-12-20 2006-12-19 Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
DK10153282.8T DK2253644T3 (da) 2005-12-20 2006-12-19 Sammensætninger og fremgangsmåder til fremstilling af en sammensætning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10153282.8T DK2253644T3 (da) 2005-12-20 2006-12-19 Sammensætninger og fremgangsmåder til fremstilling af en sammensætning

Country Status (24)

Country Link
US (4) US10508144B2 (da)
EP (2) EP1969007B1 (da)
JP (2) JP5096369B2 (da)
KR (2) KR101391457B1 (da)
CN (1) CN106589132B (da)
AU (2) AU2006330922B2 (da)
BR (2) BRPI0622251A2 (da)
CA (2) CA2634760C (da)
CY (1) CY1114887T1 (da)
DK (2) DK1969007T3 (da)
EA (1) EA017765B1 (da)
ES (2) ES2433092T3 (da)
HR (1) HRP20130975T1 (da)
IL (2) IL192098A (da)
MX (1) MX336807B (da)
NO (1) NO20082716L (da)
NZ (1) NZ597215A (da)
PE (1) PE20080556A1 (da)
PL (2) PL2253644T3 (da)
PT (2) PT2253644E (da)
SI (2) SI2253644T1 (da)
TW (2) TWI398520B (da)
WO (1) WO2007076032A2 (da)
ZA (1) ZA200805301B (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969007B1 (en) 2005-12-20 2013-08-28 Bristol-Myers Squibb Company Compositions and methods for producing a composition
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
CN107011431B (zh) 2007-01-30 2020-11-06 埃皮瓦克斯公司 调节性t细胞表位、组合物及其用途
FI4269578T3 (fi) 2008-03-06 2024-06-07 Halozyme Inc Liukoisen hyaluronidaasin suurimittainen tuotanto
US7915222B2 (en) 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CN102170919A (zh) 2008-10-06 2011-08-31 三维肽胶株式会社 组织闭塞剂
CN101995476B (zh) * 2009-08-10 2013-07-03 中国医学科学院北京协和医院 临床化学检验用液体质控血清
US9540426B2 (en) 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011069056A2 (en) 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
MX2012009283A (es) * 2010-02-12 2012-09-07 Dsm Ip Assets Bv Purificacion de anticuerpo de una unidad.
TW201134481A (en) 2010-03-12 2011-10-16 Abbott Biotherapeutics Corp CTLA4 proteins and their uses
US20120121574A1 (en) * 2010-11-15 2012-05-17 Luciano Polonelli Antimicrobial, antiviral, anticancer and immunomodulatory peptides and uses therefore
JP5847418B2 (ja) 2011-03-30 2016-01-20 富士フイルム株式会社 細胞接着性タンパク質
CA2833212C (en) * 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
EP2820149A1 (en) * 2012-02-27 2015-01-07 Biogen Idec MA Inc. High-throughput method for sialic acid quantitation
US20150140589A1 (en) * 2012-04-22 2015-05-21 Perfinity Biosciences, Inc. Automated protein digestion, recovery, and analysis
DK2867251T3 (da) * 2012-06-29 2019-11-25 Bristol Myers Squibb Co Fremgangsmåder til reduktion af glycoproteinaggregering
US10793307B2 (en) 2012-07-06 2020-10-06 3-D Matrix, Ltd. Fill-finish process for peptide solutions
EP4397768A3 (en) 2012-07-26 2024-12-18 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
WO2014149067A1 (en) * 2013-03-15 2014-09-25 Momenta Pharmaceuticals, Inc. Methods related to ctla4-fc fusion proteins
EP2996772B1 (en) 2013-05-13 2018-12-19 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
ES3037364T3 (en) 2014-03-10 2025-10-01 3 D Matrix Ltd Sterilization and filtration of peptide compositions
DK3116896T3 (da) 2014-03-10 2019-03-18 3 D Matrix Ltd Selvdannende peptidsammensætninger
WO2015164595A1 (en) 2014-04-25 2015-10-29 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
EP3207132B1 (en) 2014-10-15 2019-07-31 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
HUE054616T2 (hu) 2015-04-17 2021-09-28 Alpine Immune Sciences Inc Immunmodulátor fehérjék hangolható affinitásokkal
KR102706532B1 (ko) 2015-06-10 2024-09-19 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 질환의 치료를 위한 엑소좀의 용도
TWI579030B (zh) * 2015-12-15 2017-04-21 Ｃｇ生物技術有限公司 分離細胞之容器、系統及方法
WO2017120092A1 (en) 2016-01-06 2017-07-13 3-D Matrix, Ltd. Combination compositions
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US10613081B2 (en) * 2016-11-27 2020-04-07 Alireza Palangi Quality control system and kit for automated ELISA devices
CN110945593A (zh) * 2017-06-16 2020-03-31 通用电气健康护理生物科学股份公司 用于预测生物反应器中的过程的产出和对生物反应器中的过程建模的方法
CN109385401A (zh) * 2017-08-10 2019-02-26 北京泰德制药股份有限公司 一种表达重组蛋白的cho细胞的培养方法
WO2019060629A1 (en) * 2017-09-21 2019-03-28 Codiak Biosciences, Inc. PRODUCTION OF EXTRACELLULAR VESICLES IN A SUSPENSION OF INSULATED CELLS USING CHEMICALLY DEFINED CELL CULTURE MEDIA
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
JP7102734B2 (ja) 2018-01-09 2022-07-20 東洋製罐グループホールディングス株式会社 細胞培養方法及び装置
SMT202200264T1 (it) 2018-04-20 2022-07-21 Janssen Biotech Inc Qualificazione della colonna cromatografica nei metodi di produzione di composizioni di anticorpi anti-il12/il23
JP7652422B2 (ja) * 2018-11-02 2025-03-27 ベイジン ブイディージェイバイオ カンパニー， リミテッド 修飾されたｃｔｌａ４およびその使用方法
US11965900B2 (en) * 2018-11-09 2024-04-23 Wyatt Technology, Llc Indicating a status of an analytical instrument on a screen of the analytical instrument
WO2020251862A1 (en) * 2019-06-14 2020-12-17 Agilent Technologies, Inc. Methods and kits to improve the fluorescent signal of dmb-labeled sialic acids
US20220288095A1 (en) * 2019-07-26 2022-09-15 Lifescience As Sialic acid for use in the treatment of psoriasis
CN110554107B (zh) * 2019-08-14 2022-06-10 上海应用技术大学 一种高效液相色谱-质谱联用分析食用油中甘油三酯成分的方法
EP4062176B1 (en) 2019-11-21 2024-05-22 Bristol-Myers Squibb Company Label-free n-glycan quantification methods
CN111398308B (zh) * 2020-03-27 2023-01-17 上海健康医学院 一种片剂、胶囊铝塑泡罩包装质量自动检测方法及系统
JP7415771B2 (ja) 2020-04-24 2024-01-17 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
JP7314859B2 (ja) 2020-04-30 2023-07-26 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
US20230167153A1 (en) 2020-05-01 2023-06-01 Kashiv Biosciences, Llc An improved process of purification of protein
JP7415783B2 (ja) * 2020-05-12 2024-01-17 株式会社島津製作所 分析支援装置、分析支援方法および分析支援プログラム
WO2022036275A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Manufacturing process for protein
KR20230045615A (ko) * 2020-08-14 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 단백질을 제조하는 방법
CN112198302B (zh) * 2020-10-25 2022-12-16 中铁二局第一工程有限公司 一种细集料含泥量快速检测方法及测量工具
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
CA3113278C (en) * 2021-03-25 2025-08-12 Lumex Instruments Canada (0890278 B.C. Ltd.) Device for electrophoretic analysis of multicomponent liquid samples
WO2022208550A1 (en) * 2021-03-31 2022-10-06 Dr. Reddy's Laboratories Limited Cell culture process for fusion protein composition
CN113241192B (zh) * 2021-05-18 2023-06-20 武汉大学中南医院 一种证据合成方法和计算机设备
JP7600875B2 (ja) * 2021-06-01 2024-12-17 株式会社島津製作所 試料分析装置、試料分析方法、医薬分析装置および医薬分析方法
CA3233422A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of fusion protein
WO2023053030A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of protein
AU2022358612A1 (en) * 2021-09-28 2024-04-11 Kashiv Biosciences, Llc An improved process of purification of fusion protein
EP4448022A2 (en) * 2021-12-16 2024-10-23 Bristol-Myers Squibb Company Detergent for viral inactivation
JP2025016812A (ja) * 2021-12-16 2025-02-05 レグセル株式会社 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物
WO2023112000A2 (en) * 2021-12-17 2023-06-22 Kashiv Biosciences, Llc An improved method for separation of low molecular weight proteins
CN118871451A (zh) * 2022-03-18 2024-10-29 百时美施贵宝公司 分离多肽的方法
CN116467264B (zh) * 2023-04-14 2025-11-28 阿里健康科技(中国)有限公司 Rf2文件的生成方法、装置、设备和存储介质
US12461955B2 (en) * 2023-09-08 2025-11-04 Salesforce, Inc. Integration flow generation using large language models
CN117044627B (zh) * 2023-10-11 2023-12-15 中国科学院昆明植物研究所 一种高山植物塔黄的组培快繁及离体保存方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460694A (en) * 1981-03-26 1984-07-17 University Of Miami Bovine glycoproteins and use in diagnosing infectious mononucleosis
US4929700A (en) * 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
DE122007000078I2 (de) 1991-06-27 2011-01-13 Bristol Myers Squibb Co CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
AU3144193A (en) * 1991-11-21 1993-06-15 Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
JPH09502728A (ja) * 1993-09-15 1997-03-18 アルファ セラピューティク コーポレイション α▲下１▼−酸性糖タンパク質の精製方法及び精製物
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
JPH10501815A (ja) 1994-06-07 1998-02-17 リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミネソタ 抗原特異的ｔ細胞応答の阻害方法
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
EP2275119B1 (en) 1995-07-27 2013-09-25 Genentech, Inc. Stable isotonic lyophilized protein formulation
BR9713055A (pt) 1996-11-15 2000-04-04 Genentech Inc Processo para isolar uma neurotrofina humana recombinante, composição de neurotrofina e processo para purificar uma neurotrofina
PT1864999E (pt) 1996-11-27 2009-06-25 Genentech Inc Purificação por afinidade de um polipéptido numa matriz de proteína a
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030124614A1 (en) 1997-08-29 2003-07-03 Brighams And Womens Hospital Inc. Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
DE59813187D1 (de) 1997-12-03 2005-12-15 Roche Diagnostics Gmbh Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
DK1084136T3 (da) 1998-06-01 2005-01-03 Genentech Inc Adskillelse af monomere af et antistof fra dets multimere ved anvendelse af ionbytterchromatografi
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
WO2000065070A2 (en) 1999-04-26 2000-11-02 Genentech, Inc. Cell culture process for glycoproteins
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
ATE448241T1 (de) * 2000-03-27 2009-11-15 Genetics Inst Llc Verfahren zur reinigung stark anionischer proteine
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
HK1048126B (en) 2000-05-26 2005-03-04 Bristol-Myers Squibb Co. Soluble ctla4 mutant molecules and uses thereof
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
IL152316A0 (en) 2000-06-09 2003-05-29 Bristol Myers Squibb Co Pharmaceutical compositions and kits for treating transplant rejection
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
CA2411828A1 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules
KR100895552B1 (ko) * 2000-07-03 2009-04-29 브리스톨-마이어스스퀴브컴파니 가용성 ｃｔｌａ4 분자를 사용한 류마티스성 질환의 치료법
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US6358265B1 (en) 2000-07-18 2002-03-19 Specialized Health Products, Inc. Single-step disposable safety lancet apparatus and methods
CA2436139A1 (en) 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
ATE363541T1 (de) * 2002-03-26 2007-06-15 Lek Tovarna Farmacevtskih Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
US6872549B2 (en) 2002-03-27 2005-03-29 Immunex Corporation Methods for increasing polypeptide production
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2003088991A1 (en) 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
US20060234226A1 (en) 2002-04-26 2006-10-19 Fahner Robert L Non-affinity purification of proteins
AU2002345524A1 (en) 2002-06-19 2004-01-06 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. A process for the production of substituted phenyl ethers
MXPA05000552A (es) * 2002-07-15 2005-04-28 Immunex Corp Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
MXPA05006522A (es) * 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
TWI312368B (en) 2002-12-23 2009-07-21 Bristol Myers Squibb Compan Mammalian cell culture processes for protein production
EP1610820B2 (en) 2003-04-04 2013-08-21 Genentech, Inc. High concentration antibody and protein formulations
US7118222B2 (en) * 2003-05-12 2006-10-10 Seiko Epson Corporation Optical device and protector
DK1639014T3 (da) * 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
KR20090087514A (ko) 2003-08-04 2009-08-17 브리스톨-마이어스 스큅 컴퍼니 가용성 ｃｔｌａ4 돌연변이체 분자를 사용한 심혈관 질환의 치료 방법
US7427659B2 (en) * 2003-10-24 2008-09-23 Amgen Inc. Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
EP1969007B1 (en) 2005-12-20 2013-08-28 Bristol-Myers Squibb Company Compositions and methods for producing a composition
EA014232B1 (ru) 2005-12-20 2010-10-29 Бристол-Маерс Сквибб Компани Стабильные белковые препараты
US20100267932A1 (en) 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins
KR101770312B1 (ko) 2006-08-28 2017-08-22 아레스 트레이딩 에스.에이. Ｆｃ­함유 단백질을 정제하는 방법

Also Published As

Publication number Publication date
DK2253644T3 (da) 2014-01-13
NZ597215A (en) 2012-11-30
CA2836123A1 (en) 2007-07-05
ES2439641T3 (es) 2014-01-24
JP5096369B2 (ja) 2012-12-12
US12030923B2 (en) 2024-07-09
IL192098A (en) 2014-01-30
SI1969007T1 (sl) 2014-03-31
KR20080090428A (ko) 2008-10-08
NO20082716L (no) 2008-09-19
SI2253644T1 (sl) 2014-03-31
US20190092835A1 (en) 2019-03-28
HRP20130975T1 (hr) 2013-11-22
BRPI0620178B1 (pt) 2022-08-23
PL1969007T4 (pl) 2014-04-30
JP2010116402A (ja) 2010-05-27
EP2253644B1 (en) 2013-10-16
CN106589132B (zh) 2022-03-29
ES2433092T3 (es) 2013-12-09
CN106589132A (zh) 2017-04-26
WO2007076032A3 (en) 2008-04-03
AU2010241289B2 (en) 2012-09-13
KR20120010275A (ko) 2012-02-02
US20090252749A1 (en) 2009-10-08
JP5097194B2 (ja) 2012-12-12
EP1969007A2 (en) 2008-09-17
BRPI0622251A2 (pt) 2011-07-19
PT2253644E (pt) 2014-01-23
CY1114887T1 (el) 2016-12-14
WO2007076032A2 (en) 2007-07-05
TWI398520B (zh) 2013-06-11
PL1969007T3 (pl) 2014-01-31
CA2634760C (en) 2014-09-09
CA2634760A1 (en) 2007-07-05
US10808021B2 (en) 2020-10-20
BRPI0620178A2 (pt) 2010-06-29
JP2009520503A (ja) 2009-05-28
PL2253644T3 (pl) 2014-04-30
PT1969007E (pt) 2013-12-10
CA2836123C (en) 2017-09-12
TW201313742A (zh) 2013-04-01
HK1121173A1 (en) 2009-04-17
EA200801571A1 (ru) 2010-02-26
AU2006330922A1 (en) 2007-07-05
PE20080556A1 (es) 2008-06-13
US20210246188A1 (en) 2021-08-12
AU2010241289A1 (en) 2010-12-02
KR101398713B1 (ko) 2014-06-12
US10508144B2 (en) 2019-12-17
TW200745334A (en) 2007-12-16
EA017765B1 (ru) 2013-03-29
MX336807B (es) 2016-02-02
AU2006330922B2 (en) 2012-07-26
KR101391457B1 (ko) 2014-05-19
US10941189B2 (en) 2021-03-09
ZA200805301B (en) 2012-11-28
IL229904A0 (en) 2014-01-30
TWI423986B (zh) 2014-01-21
US20190062399A1 (en) 2019-02-28
IL192098A0 (en) 2008-12-29
EP1969007B1 (en) 2013-08-28
EP2253644A1 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
DK2253644T3 (da) Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
FR22C1008I2 (fr) Composition immunogène
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK2460820T3 (da) PCV2-immunogene sammensætninger og fremgangsmåder til fremstilling af sådanne sammensætninger
DK2001611T3 (da) Fremgangsmåde og sammensætning til oprensning af jord
DK1856374T3 (da) Sammensætning og fremgangsmåde til fremstilling af et støttemiddel
DK2041071T3 (da) Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK2135603T3 (da) Sammensætninger og fremgangsmåder til øgning af insulinsensitivitet
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK3207941T3 (da) Fremgangsmåder og sammensætninger på basis af diphtheritoksin-interleukin-3-konjugater
DK1730259T3 (da) Fremgangsmåde til fremstilling af en sammensætning omfattende tørrede mikroorganismer
DK3308788T3 (da) Sammensætninger og fremgangsmåder til modulering af smn2-splejsning
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
EP1788047A4 (en) WATER REPELLENT / OIL-REPELLING COMPOSITION
DK1898829T3 (da) Fremgangsmåde til fremstilling af en tandprotesedel og således fremstillet tandprotesedel
EP1923431A4 (en) Curable composition
EP1967540A4 (en) HARDENING COMPOSITION
DE602006020159D1 (de) Härtbare silikonzusammensetzung
DK1891208T3 (da) Hidtil ukendte cellulære sammensætninger og fremgangsmåder til fremstilling deraf
NO20055686D0 (no) Sammensetning
EP1882713A4 (en) HARDENING COMPOSITION
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer